Novartis | Betriebsaufwand



Operating Expenses Veränderung Datum
AbbVie USD 16.59B 5.96B 2024-12
Alcon AG USD 2.11B 15M 2024-12
Almirall EUR 195.38M 68.92M 2024-06
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 12.86B 2.06B 2024-12
Autolus Therapeutics Ltd 67.65M 67.65M 2024-09
Bayer EUR 8.2B 5.59B 2024-12
Biogen USD 2.01B 13.3M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Fresenius EUR 5.16B 287M 2024-12
Fresenius Medical Care EUR 4.83B 528.89M 2024-12
Galapagos EUR 138.22M 24.07M 2024-12
Genmab DKK 4.25B 812M 2024-12
Gilead Sciences USD 5.12B 1.54B 2024-12
GlaxoSmithKline GBP 7.42B 402M 2024-12
GRIFOLS EUR 1.6B 128.03M 2024-12
Hikma Pharmaceutical USD 1.24B 87M 2024-06
J&J USD 18.63B 500M 2024-12
Lonza CHF 2.52B 776M 2024-06
Merck EUR 4.17B 391M 2024-09
Merck USD 11.33B 1.4B 2024-12
Novartis USD 11.28B 1.73B 2024-12
Novartis USD 10.15B 579M 2024-12
Novo Nordisk 37.49B 4.64B 2024-09
Orion EUR 341.7M 72.4M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Philips EUR 4.85B 806M 2024-12
Recordati EUR 394.73M 34.25M 2024-09
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 10.07B 969M 2024-09
UCB EUR 1.23B 1.31B 2024-06



Novartis Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.